We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Events

01 Mar 2020 - 05 Mar 2020
05 Mar 2020 - 07 Mar 2020
11 Mar 2020 - 13 Mar 2020

Luminex Acquires MilliporeSigma Flow Cytometry Portfolio

By LabMedica International staff writers
Posted on 08 Jan 2019
Print article
Image: Luminex has acquired the flow cytometry portfolio of MilliporeSigma (Photo courtesy of iStock).
Image: Luminex has acquired the flow cytometry portfolio of MilliporeSigma (Photo courtesy of iStock).
Luminex Corporation (Austin, Texas, USA) has completed its previously announced acquisition of MilliporeSigma's (Burlington, MA, USA) flow cytometry portfolio.

Luminex offers a wide range of solutions applicable in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex's newly acquired flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis, as well as the Guava portfolio of systems based on microcapillary technologies.

"We are pleased to announce the completion of this transaction and excited to welcome the talented MilliporeSigma flow cytometry team to the Luminex family," said Homi Shamir, president and CEO of Luminex. "This acquisition enables us to enhance our existing offering of flow-based detection systems, while simultaneously expanding our direct interactions with researchers conducting cellular analysis."

"The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we are well-positioned to support customers today and into the future," said Shamir. "With this acquisition, we now have expanded our installed based to include more than 5,000 flow cytometry systems worldwide, adding to our impressive footprint and creating the potential for additional meaningful growth."


Print article

Channels

Molecular Diagnostics

view channel
Image: Illustration of a 2019- novel coronavirus (nCoV) virion (Photo courtesy of Alissa Eckert, MS/CDC).

The Randox Laboratories Diagnostic Test Distinguishes Coronavirus from Other Respiratory Infections

The global health diagnostics company Randox Laboratories (Crumlin, United Kingdom) has announced the release of a rapid diagnostic test for the COVID-19 strain of coronavirus. A novel coronavirus of... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.